Stock DNA
Pharmaceuticals & Biotechnology
CAD 7 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.93
370.52%
-6.81
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Mar 2025)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
20.0%
0%
20.0%
3 Years
-40.0%
0%
-40.0%
4 Years
-82.35%
0%
-82.35%
5 Years
0%
0%
0.0%
Ayurcann Holdings Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
98.41%
EBIT Growth (5y)
-208.45%
EBIT to Interest (avg)
-2.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
11.89
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.73%
ROE (avg)
6.99%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.81
EV to EBIT
-2.82
EV to EBITDA
-4.59
EV to Capital Employed
7.75
EV to Sales
0.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-274.99%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
7.60
7.50
1.33%
Operating Profit (PBDIT) excl Other Income
-0.20
0.30
-166.67%
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.60
-0.10
-500.00%
Operating Profit Margin (Excl OI)
-51.20%
10.50%
-6.17%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 1.33% vs -9.64% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -500.00% vs 75.00% in Dec 2024
Annual Results Snapshot (Consolidated) - Jun'24
Jun'24
Jun'23
Change(%)
Net Sales
25.20
12.50
101.60%
Operating Profit (PBDIT) excl Other Income
-2.00
-4.60
56.52%
Interest
0.70
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.00
-5.30
24.53%
Operating Profit Margin (Excl OI)
-129.20%
-427.80%
29.86%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2024 is 101.60% vs 32.98% in Jun 2023
Consolidated Net Profit
YoY Growth in year ended Jun 2024 is 24.53% vs -70.97% in Jun 2023
About Ayurcann Holdings Corp. 
Ayurcann Holdings Corp.
Pharmaceuticals & Biotechnology
Canada Coal Inc. is a Canada-based junior resource mining company. The Company's principal business is the acquisition and exploration of coal properties in Nunavut, Canada. Its coal licenses are located on Ellesmere Island and Axel Heiberg Islands, Nunavut Territory, Canada. The project consists of 75 coal licenses geographically distributed as nine discrete exploration areas occupying a total of 989,521 hectares. The exploration areas consist of Fosheim Peninsula, Sor Fiord/Stenkul Fiord, Strathcona Fiord, Vesle Fiord/South Fosheim, May Point, Bache Peninsula, Li Fiord, Good Friday Bay and Mokka Fiord. The licenses are held by the Company's two subsidiaries: 5200 Nunavut Ltd. and Canadian Sovereign Coal Corp. The Company is at the early stages of exploration on its projects and has not generated revenues from its operations.
Company Coordinates 
Company Details
5213 Durie Road , MISSISSAUGA ON : L5M-2C6
Registrar Details






